Search the Newsreel

BIOMARIN PHARMACEUTICAL INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $98

BMO has initiated coverage on BioMarin Pharmaceutical Inc. (BMRN.O) with an "Outperform" rating. The firm has set a price target of $98 for the biotechnology company. This information was reported by Reuters.

Earnings Update: Here's Why Analysts Just Lifted Their Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Price Target To HK$612

Form 8K Silo Pharma Inc For: 19 August By Investing.com

This article announces that Silo Pharma Inc. filed a Form 8K on August 19. The filing is available through Investing.com, which also provides real-time market data for various financial instruments. The brief news item includes a link to view comments and references the company's …

Millennium reports 3.38M-share passive stake in Vanda (NASDAQ: VNDA)

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a collective passive stake of 3,376,401 shares in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), representing 5.6% of the outstanding common stock. They hold shared voting and dispositive power over these shares, indicating …

Form 8K Sonoma Pharmaceuticals Inc For: 19 August By Investing.com

This article reports on the filing of a Form 8K by Sonoma Pharmaceuticals Inc. on August 19th. The content is brief, primarily serving as an announcement of the SEC filing for the company. Sonoma Pharmaceuticals Inc. (SNOA) saw a stock increase of 4.62% as …

Why Alpha Metallurgical Resources Is Surging 10.4%: Jefferies Maintains Hold

Alpha Metallurgical Resources (AMR) surged 10.4% after Jefferies upgraded its price target from $150 to $165, while maintaining a Hold rating. The stock closed at $187.09, exceeding the new target and indicating renewed investor confidence despite the analyst's tempered outlook. Investors should monitor coking …

BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is expanding its rare-disease business with the acquisition of Alesta Therapeutics for $275 million upfront. The deal gives BioMarin access to ALE1, an oral treatment being developed for hypophosphatasia (HPP), a rare genetic bone disorder. ALE1 is still in early-stage …

Pasatru’s FDA Approval Puts Regeneron’s Rare-Disease Playbook To The Test

Regeneron's drug Pasatru has received FDA approval for the treatment of FOP. This approval is seen as a crucial test for Regeneron's strategy in the rare-disease market. The article suggests this event will highlight how Regeneron's approach to rare diseases fares following this significant …

Takeda (TAK) Q2 2026 Results: EPS Beats Its Estimate for the Current Session; Market Move

Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ARWR

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) reported a significant revenue increase to $829.45 million USD last year, primarily from its RNA Interference Therapeutics segment. This segment also contributed the entire $829.45 million USD from the United States market. This marks a substantial rise from the …

Enphase Energy Inc. stock outperforms competitors on strong trading day

Shares of Enphase Energy Inc. (ENPH) rose by 4.76% to $39.37 on Wednesday, outperforming competitors during a strong trading session for the overall stock market. The S&P 500 Index and Dow Jones Industrial Average also saw gains, with ENPH's increase ending a three-day losing …

Aurinia settles Lupkynis patent litigation with Teva

[Intellectual Property] stocknshares * Teva Pharmaceutical Industries (TEVA [https://seekingalpha.com/symbol/TEVA]) will not be able to launch a generic version of Aurinia Pharmaceuticals' (AUPH [https://seekingalpha.com/symbol/AUPH]) Lupkynis (voclosporin) until Dec. 7, 2036, at the earliest under a settlement. * Teva had filed an Abbreviated New Drug Application …

MediaAlpha (NYSE: MAX) director sells 34K shares for RSU taxes

MediaAlpha, Inc. director Eugene Nonko sold a total of 34,461 Class A Common Stock shares between August 17-19, 2026. These transactions, conducted under a Rule 10b5-1 trading plan, were primarily to cover taxes from vesting Restricted Stock Units (RSUs). The weighted-average sale prices for …

Silo Pharma Acquires Software and IP From Parkview Consulting for 165,000 Shares

Silo Pharma has acquired software, technology, domain names, and related intellectual property from Parkview Consulting. As consideration, Silo Pharma issued 165,000 shares of common stock, subject to a lock-up period of up to 12 months. This agreement aims to expand Silo Pharma's technology capabilities.

Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells 12,980 Shares

Takeda Pharmaceutical insider Nicola Deidre Petal Greenway sold 12,980 shares of the company's stock for a total of $235,067.80. This transaction reduced her holdings by 24.48%, leaving her with 40,049 shares. The sale occurred on August 18th at an average price of $18.11, following …

Alphabet Stock Surged When Its AI Spending Found Customers

Alphabet's stock significantly outperformed the market and its peers over the past year, returning 69.6% compared to the S&P 500's 20.3%. This surge is attributed to its AI spending finding customers, particularly in Google Cloud, which saw 82% revenue growth and improved operating margins. …

Die Parker-Hannifin-Aktie setzt ihre Rally mit zweistelligem Gewinnwachstum fort

SOPHiA GENETICS (NASDAQ: SOPH) officer plans additional 8,000-share sale

An officer at SOPHiA GENETICS (NASDAQ: SOPH), Zhenyu Xu, intends to sell an additional 8,000 shares of common stock under Rule 144, valued at $60,960. These shares are founder shares acquired in 2012 and are held at Morgan Stanley Smith Barney LLC Executive Financial …

Zenas BioPharma (ZBIO) affiliate plans August 2026 share sale

Zenas BioPharma (ZBIO) announced via a Rule 144 notice that its affiliate, Zebra Aggregator, plans to sell up to 1,000,000 common shares through J.P. Morgan Securities LLC on August 19, 2026. This proposed sale has an aggregate market value of $31,910,000 and the shares …

Family trust tied to BridgeBio (NASDAQ: BBIO) plans new stock sale

A family trust associated with BridgeBio Pharma, Inc. (BBIO), the Kumar Haldea Family Irrevocable Trust, intends to sell 30,000 shares of common stock valued at approximately $2.49 million. This sale, detailed in a Form 144 SEC filing, follows previous 10b5-1 sales by Neil Kumar …

Why Is Ionis Pharmaceuticals (IONS) Pushing RG-6299 Into A Pivotal Phase III Trial?

Ionis Pharmaceuticals, in collaboration with Roche and Chugai, is advancing RG-6299, an antisense therapy for IgA nephropathy, into a global Phase III trial. This move targets an unmet medical need and aligns with Ionis' strategy of leveraging its RNA platform through partnerships for late-stage …

Phibro Animal Health to report Q4 FY26 results on August 26

Phibro Animal Health Corporation (NASDAQ: PAHC) is scheduled to announce its fourth quarter and fiscal year 2026 financial results after market close on Wednesday, August 26, 2026. Management will host a conference call and webcast on Thursday, August 27, 2026, at 9:00 am ET …

Guardian Pharmacy CEO to join a Sept. 15 fireside chat for investors

Guardian Pharmacy Services, Inc. (NYSE: GRDN) announced that its President and CEO, Fred Burke, will participate in a fireside chat at the Jefferies Healthcare Services Conference on September 15, 2026. The event, starting at 2:25 p.m. CST, will be accessible via a live audio …

Philip Morris International Inc. stock underperforms Wednesday when compared to competitors despite daily gains

Philip Morris International Inc. (PM) shares increased by 1.23% on Wednesday, closing at $189.93. Despite this gain, the stock underperformed compared to the broader market, as the S&P 500 Index rose by 0.21% and the Dow Jones Industrial Average gained 0.22%. This marks the …

Parker-Hannifin (NYSE: PH) exec sells shares, gifts 95 more

Parker-Hannifin Corp executive Scott Patrick, VP & Pres-Fluid Conn. Grp., reported selling 1,235 shares of the company's common stock on August 17, 2026, at a weighted average price of $1,056.98 per share. Additionally, he gifted 95 shares of common stock on August 18, 2026. …

Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 4.48% on Aug 19: Drivers Behind the Movement

Alpha Teknova at Micro-Cap Virtual Conference: clinical growth in focus

Alpha Teknova recently presented at the Micro-Cap Virtual Conference, highlighting significant growth in its clinical products division and improved financial performance. The company reported record Q2 2025 revenue of $12.2 million and raised its full-year guidance, with adjusted EBITDA expected to turn positive in …

Innate Pharma (IPHA) sells 17.6M shares to fund ADCs, cash runway to Q3 2026

Innate Pharma (IPHA) has successfully raised approximately €30.0 million in gross proceeds, or €27.6 million net, through a private placement of 17,647,059 new ordinary shares at €1.70 each. The funds are primarily intended to support the clinical development of its Nectin-4 ADC IPH4502 and …

Eupraxia (Nasdaq: EPRX) lines up $300M in securities offerings

Eupraxia Pharmaceuticals Inc. (EPRX) has filed an amended Form F-10 shelf prospectus to register up to $300 million in various securities, including common and preferred shares, debt, warrants, subscription receipts, and units. This filing provides a flexible framework for future capital raises over a …

Crinetics Pharmaceuticals to supplement proxy after shareholder suits ahead of $85-per-share Vertex merger

Crinetics Pharmaceuticals announced it will voluntarily supplement its proxy disclosures following shareholder complaints and demand letters regarding the proposed $85.00-per-share merger with Vertex. Despite denying allegations of false or omitted information in the initial proxy, Crinetics will file supplemental disclosures to avoid delays and …

Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow

Madrigal Pharmaceuticals (MDGL) stock appears undervalued based on sales, trading at a P/S ratio of 9.4x compared to an industry average of 11.1x and a fair estimate of 15.0x. Despite a significant 5.4x gain over five years, a recent pullback has prompted a re-evaluation …

Takeda (NYSE: TAK) officer plans sale of 19,651 shares

An officer of Takeda Pharmaceutical Co Ltd (TAK), Andrew Stewart Plump, plans to sell 19,651 shares of common stock through Fidelity Brokerage Services LLC on or about August 19, 2026. The shares, acquired as RSU's and PSU's on August 20, 2020, are held in …

Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026 Morgan Stanley 24th Annual Global Healthcare Conference at …

Crinetics (CRNX) projects $1B+ 2030 revenue for Vertex deal

CSCI Reports Earnings — What Canadian Investors Should Know

Pharvaris BV (NASDAQ: PHVS) Share Price, PHVS Stock News, PHVS Share Price & Updates